{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T10:59:15Z","timestamp":1768733955998,"version":"3.49.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,16]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal enzyme, \u03b1-galactosidase A (\u03b1-Gal A), which leads to globotriaosylceramide (Gb3) deposition in multiple tissues. The current management of FD is enzyme replacement therapy (ERT). We report on the efficacy and safety of a new agalsidase beta, ISU303, in FD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Ten patients (7 males, 3 females) were enrolled and administered a 1 mg\/kg dose of ISU303, every other week for 6 months. The primary endpoint was the normalization of plasma Gb3 level. The secondary endpoints were the changes from baseline in urine Gb3 and the plasma and urine lyso-globotriaosylsphingosine (lyso-Gb3) level. Echocardiography, renal function test, and pain-related quality of life were also assessed before and after administration. Safety evaluation was performed including vital signs, laboratory tests, electrocardiograms, antibody screening tests, and adverse events at each visit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>At 22 weeks of treatment, plasma and urine Gb3 level decreased by a mean of 4.01\u2005\u00b1\u20051.29 \u03bcg\/mL (range 2.50\u20135.70) (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u2005.005) and 1.12\u2005\u00b1\u20051.98 \u03bcg\/mg Cr. (range 0.04\u20135.65) (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u2005.017), respectively. However, no significant difference was observed in plasma and urine lyso-Gb3 levels. Echocardiography also was not changed. Renal function and pain-related quality of life showed improvements, but there was no clinical significance. No severe adverse events were observed. Only 1 patient developed an anti-drug antibody without neutralizing activity during the trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study showed the efficacy and safety of ISU303. Treatment with ISU303 significantly resulted in plasma and urine Gb3 decrease in patients with FD. These results suggest that ISU303 is safe and effective and can alternative ERT for FD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030345","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T13:13:33Z","timestamp":1663593213000},"page":"e30345","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease"],"prefix":"10.1097","volume":"101","author":[{"given":"Soojin","family":"Hwang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"},{"name":"Medical Genetics Center, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-Shik","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Seong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong Kun","family":"Cheon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Hwa","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hanyang University Medical Center, Seoul, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunha","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Ho","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Hye","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"},{"name":"Medical Genetics Center, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders.","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease.","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease.","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e7387","DOI":"10.1097\/MD.0000000000007387","article-title":"Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: underdiagnosis of late-onset phenotype.","volume":"96","author":"Choi","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/jhg.2010.58","article-title":"Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns.","volume":"55","author":"Lee","year":"2010","journal-title":"J Hum Genet"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","article-title":"Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.","volume":"107","author":"Pisani","year":"2012","journal-title":"Mol Genet Metab"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-016-0607-y","article-title":"Migalastat: first global approval.","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1083\/jcb.119.5.1137","article-title":"Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion.","volume":"119","author":"Ioannou","year":"1992","journal-title":"J Cell Biol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jcph.262","article-title":"First-in-human study with new recombinant agalsidase beta (ISU303) in healthy subjects.","volume":"54","author":"Kim","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease.","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"R20-20250504","first-page":"95","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for fabry disease.","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Rep"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/jmedgenet-2020-107162","article-title":"Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort.","volume":"58","author":"Effraimidis","year":"2021","journal-title":"J Med Genet"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - a systematic literature review by a European panel of experts.","volume":"126","author":"Germain","year":"2019","journal-title":"Mol Genet Metab"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry.","volume":"15","author":"Germain","year":"2013","journal-title":"Genet Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/jhg.2016.78","article-title":"Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.","volume":"61","author":"Kim","year":"2016","journal-title":"J Hum Genet"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","article-title":"Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.","volume":"28","author":"Eto","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry.","volume":"12","author":"Watt","year":"2010","journal-title":"Genet Med"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jmedgenet-2017-104704","article-title":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.","volume":"54","author":"Heo","year":"2017","journal-title":"J Med Genet"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","article-title":"Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease.","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1634\/theoncologist.2017-0126","article-title":"The concept of biosimilars: from characterization to evolution\u2014a narrative review.","volume":"23","author":"Farhat","year":"2018","journal-title":"Oncologist"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","article-title":"Identifying key benefits in european off-patent biologics and biosimilar markets: it is not only about price!.","volume":"34","author":"Dutta","year":"2020","journal-title":"BioDrugs"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4161\/mabs.3.2.15005","article-title":"Worldwide experience with biosimilar development.","volume":"3","author":"McCamish","year":"2011","journal-title":"MAbs"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nbt1104-1357","article-title":"How similar do \u201cbiosimilars\u201d need to be?","volume":"22","author":"Schellekens","year":"2004","journal-title":"Nat Biotechnol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:44:02Z","timestamp":1746333842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":33,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030345","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}